Copay Assistance Programs Halted By GlaxoSmithKline, Merck & Co., Inc.

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Merck and Co Inc and GlaxoSmithKline Plc are not reimbursing drug co-payments for patients who purchase their health insurance through state and federal exchanges set up under the Obamacare program. The two drugmakers said their decision, first reported by Bloomberg News, is based on uncertainty about whether insurance programs offered under the Affordable Care Act are governed by federal laws that ban kickbacks to businesses. To cap rising healthcare costs and give consumers more incentive to reduce spending, insurers in recent years have increased the out-of-pocket costs patients are expected to pay for medications.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC